Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Category

Europe

Health technology assessment, pricing and access across Europe, including EU-level joint clinical assessment and the national systems that still decide funding. Coverage spans the major markets and the smaller systems that often move first.

718 articles in this topic.

Articles in this category

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

11/16/2026

NICE Draft Guidance Backs Capsule Sponge Tests for Oesophageal Cancer

NICE draft guidance recommends Cytosponge and EndoSign to help detect oesophageal cancer and Barrett's oesophagus. The tests need no sedation and can be done outside hospital. #SyenzaNews #MarketAccess #HealthTech
Read Article →
CHMP November 2026 Recommends Seven New Medicines for Approval

11/16/2026

CHMP November 2026 Recommends Seven New Medicines for Approval

EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

11/16/2026

Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet

The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

11/13/2026

Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024

Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

11/12/2026

US MFN Drug Pricing: A 25% German Price Rise Would Cut Medicaid Savings by 3.8%

A preprint led by Thomas Hwang models how German price changes affect US Medicaid MFN savings and German statutory health insurance spending.
Read Article →
The EU HTA Regulation: What Latin America Can Learn

11/12/2026

The EU HTA Regulation: What Latin America Can Learn

A PAHO, RedETSA and HTAi webinar on the EU HTA Regulation: what Latin American agencies can reuse from joint clinical assessments, and which elements may be hard to adapt.
Read Article →
Artificial Intelligence in Medicine Regulation: From Concept to Practice

11/12/2026

Artificial Intelligence in Medicine Regulation: From Concept to Practice

EMA says it is moving artificial intelligence in medicine regulation from concept to practice. Its timeline runs from a 2021 joint workshop to research priorities published in August 2026. #SyenzaNews #MarketAccess #drugregulation
Read Article →
EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027

11/12/2026

EMA Draft Guideline on Predictive Biomarker Assays Opens Public Consultation to 31 March 2027

The European Medicines Agency has opened public consultation on its draft guideline on predictive biomarker assays. Comments are accepted from 9 November 2026 until 31 March 2027.
Read Article →
Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B

11/6/2026

Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B

INFARMED recommends public funding for Refixia nonacog beta pegol in children under 12 with haemophilia B, based on two single-arm trials. #SyenzaNews #MarketAccess
Read Article →
Recent Zolgensma safety concerns: what Novartis has reported

11/6/2026

Recent Zolgensma safety concerns: what Novartis has reported

SMA Europe has relayed Novartis's figures on tumour reports in patients previously treated with Zolgensma, including two cases of vector DNA integration.
Read Article →
Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit

11/6/2026

Dupilumab Chronic Spontaneous Urticaria: G-BA Finds No Proven Added Benefit

The G-BA has found no proven added benefit for dupilumab in chronic spontaneous urticaria, compared with omalizumab plus second-generation H1 antihistamines.
Read Article →
EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment

11/4/2026

EMA Mid-Year Report 2026: Reform, Supply and the First Joint Clinical Assessment

The EMA mid-year report 2026 records 485 scientific advice requests in the first half, the first joint clinical assessment under the HTA Regulation and progress on the new pharmaceutical law. #SyenzaNews #MarketAccess
Read Article →

Related topics